fbpx

Stay Informed. Stay Competitive. Get Free Email Updates Dow 30 & Emerging Growth

Stay Informed. Stay Competitive.

Get Free Updates

Dow 30 & Emerging Growth

Johnson & Johnson Releases A Q2 Earnings Beat – Medical Device Unit Reported 62.7% Increase

By John F. Heerdink, Jr.

Johnson & Johnson (JNJ) reported earnings exceeding analyst estimates reporting an adjusted EPS of $2.48 per share vs $2.27 expected. Revenue of $23.31 billion was reported, versus $22.21 billion expected. Johnson expects to sell $2.5 billion of its Covid-19 vaccine this year, even as its effectiveness against the delta variant is under question. Its pharmaceutical unit, which developed the single-shot Covid vaccine, reported $12.59 billion in revenue, a 17.2% year-over-year increase.

Key Release Highlights:

  • The company’s consumer unit, which makes products such as Neutrogena face wash and Listerine, generated $3.7 billion in revenue, up 13.3% from a year earlier.
  • Its medical device unit reported $6.9 billion, a 62.7% increase.
  • Global sales of the Covid vaccine in the second quarter were $164 million.
  • The company revised its outlook for the year and now expects revenue from $92.5 billion to $93.3 billion, higher than its prior forecast of $89.3 billion to $90.3 billion.
  • A full-year profit of $9.50 to $9.60 per share is expected, in comparison to its earlier forecast of $9.30 to $9.45 per share.

The earnings results come a day after a new study reported that the J&J vaccine is less effective against the delta and lambda variants than the earlier virus strain. According to the Centers for Disease Control and Prevention, Delta, a dominant variant in the U.S., now accounts for an estimated 83% of infections in the nation. Researchers are now suggesting that a booster dose may be needed for J&J recipients.

 Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare-focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.

If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus. 


Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.

(Read Original Story: Johnson & Johnson expects $2.5 billion in global sales from Covid vaccine this year in CNBC)


YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us